{
    "Clinical Trial ID": "NCT00467844",
    "Intervention": [
        "INTERVENTION 1: ",
        "  GTx-024 1 mg",
        "[Not Specified]",
        "INTERVENTION 2: ",
        "  GTx-024 3 mg",
        "[Not Specified]"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  To be eligible for participation in this study, subjects must meet all of the following criteria:",
        "  have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.",
        "  be prior to initiation of or between cycles of chemotherapy.",
        "  have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)",
        "  % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%",
        "  If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.",
        "  have a life expectancy of >6 months",
        "  FEMALES - be clinically confirmed as postmenopausal",
        "  MALES - over 45 years of age",
        "  ECOG score 1",
        "Exclusion Criteria:",
        "  Subjects with any of the following will NOT be eligible for enrollment in this study:",
        "  history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection",
        "  Cardiovascular: No uncontrolled hypertension",
        "  Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV",
        "  Currently taking testosterone, OXANDRIN\u00ae (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)",
        "  Currently taking megestrol acetate (MEGACE\u00ae), dronabinol (MARINOL\u00ae), or any prescription medication intended to increase appetite or treat unintentional weight loss"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Efficacy of GTx-024 on Total Body Lean Mass.",
        "  Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.",
        "  Time frame: Baseline to Four Months",
        "Results 1: ",
        "  Arm/Group Title: GTx-024 1 mg",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 32",
        "  Median (Full Range)",
        "  Unit of Measure: kg  1.55        (-2.06 to 12.64)",
        "Results 2: ",
        "  Arm/Group Title: GTx-024 3 mg",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 34",
        "  Median (Full Range)",
        "  Unit of Measure: kg  0.98        (-4.84 to 11.54)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 14/53 (26.42%)",
        "  Anaemia 3/53 (5.66%)",
        "  Febrile Neutropenia 2/53 (3.77%)",
        "  Neutropenia 1/53 (1.89%)",
        "  Pancytopenia 0/53 (0.00%)",
        "  Thrombocytopenia 0/53 (0.00%)",
        "  Atrial Fibrillation 1/53 (1.89%)",
        "  Myocardial infarction 1/53 (1.89%)",
        "  Diarrhoea 1/53 (1.89%)",
        "  Dysphagia 0/53 (0.00%)",
        "  gastric ulcer perforation 0/53 (0.00%)",
        "  lower gastrointestinal haemorrhage 0/53 (0.00%)",
        "Adverse Events 2:",
        "  Total: 15/54 (27.78%)",
        "  Anaemia 0/54 (0.00%)",
        "  Febrile Neutropenia 0/54 (0.00%)",
        "  Neutropenia 1/54 (1.85%)",
        "  Pancytopenia 0/54 (0.00%)",
        "  Thrombocytopenia 1/54 (1.85%)",
        "  Atrial Fibrillation 0/54 (0.00%)",
        "  Myocardial infarction 0/54 (0.00%)",
        "  Diarrhoea 0/54 (0.00%)",
        "  Dysphagia 0/54 (0.00%)",
        "  gastric ulcer perforation 0/54 (0.00%)",
        "  lower gastrointestinal haemorrhage 1/54 (1.85%)"
    ]
}